Baidu
map

政策与人文

订阅

MedSci主页 / 所有栏目 / 政策与人文

昆泰在I、II、III期临床研究市场报告中被誉为**提供商

2013-08-13 MedSci MedSci原创

昆泰临床研究
关注

北卡罗来纳州研究三角园区--(美国商业资讯)--根据行业标准研究(ISR)2013年I期临床研究发展趋势和市场展望报告(2013 Phase I Study Trends and Market Outlook Report)中对119名制药和生物技术专业人士所进行的调查，昆泰(Quintiles)成为首选I期临床研究服务提供商，并且被最多次援引为全球领先的复杂研究提供商。不久前，在5月份发布

美国昆泰跨国公司 (Quintiles Transnational Corp.)

北卡罗来纳州研究三角园区--(美国商业资讯)--根据行业标准研究(ISR)2013年I期临床研究发展趋势和市场展望报告(2013 Phase I Study Trends and Market Outlook Report)中对119名制药和生物技术专业人士所进行的调查，昆泰(Quintiles)成为首选I期临床研究服务提供商，并且被最多次援引为全球领先的复杂研究提供商。不久前，在5月份发布的一份独立ISR报告中，昆泰因其在II/III期临床研究中的顶尖服务质量被公认为业内领袖。

昆泰早期临床开发高级副总裁、医学博士Oren Cohen表示：“随着候选药物分子及其生物靶标更加复杂化，且I期临床研究进入患者人群，因而早期临床开发格局也继续在复杂性方面不断提高。我们很高兴 能够成为业内公认的首选提供商，因为这反映了我们在诸多方面的能力，包括在越来越复杂的环境下提供复杂研究的能力，与我们的客户携手开发决策途径的能力， 从而能够充满信心地决定是否要进入下一阶段。我们的科技专长和综合服务可帮助客户尽可能地作出良好发展决策。”

调查的受访者肩负进行I期临床研究和外包活动的责任和决策权，他们从所有临床研究组织(CRO)中选取昆泰作为首选提供商。此外，根据选择复杂研究 提供商所考量的一些最重要因素，如治疗专长、科技知识、对患者人群的掌握、患者/志愿者招募策略、丰富的成功经验和整体价值，调查受访者还将昆泰列为最频 繁援引的复杂研究服务提供商，即制药公司在应对复杂研究时所求助的提供商。

如需了解更多有关ISR报告方面的信息，请访问：http://www.isrreports.com/product/2013-phase-i-study-trends-and-market-outlook/。

关于昆泰

昆泰(Quintiles, NYSE: Q)是世界最大的生物制药开发和商业外包服务提供商，该公司的业务网络涵盖约100个国家，拥有员工27,000多名。市面上前50位的所有最畅销药品均 由该公司帮助开发或实现商业化。昆泰凭借其服务的深度和广度，运用广泛的治疗、科学和分析专项技能，为生物制药和健康科学客户在日益复杂的环境中导航，帮 助他们在交付更佳的医疗保健成果方面提升效率和功效。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649953, encodeId=ac9c16499533a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 26 09:37:00 CST 2013, time=2013-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915782, encodeId=ce391915e828d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu May 08 18:37:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050140, encodeId=3604205014067, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Dec 07 14:37:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652697, encodeId=152b165269ea1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 10 12:37:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524540, encodeId=cbb11524540e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594334, encodeId=2c0b1594334d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=)]
    2013-08-26 huiwelcome

    #II期临床研究#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1649953, encodeId=ac9c16499533a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 26 09:37:00 CST 2013, time=2013-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915782, encodeId=ce391915e828d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu May 08 18:37:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050140, encodeId=3604205014067, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Dec 07 14:37:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652697, encodeId=152b165269ea1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 10 12:37:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524540, encodeId=cbb11524540e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594334, encodeId=2c0b1594334d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=)]
    2014-05-08 juliusluan78

    #III#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1649953, encodeId=ac9c16499533a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 26 09:37:00 CST 2013, time=2013-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915782, encodeId=ce391915e828d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu May 08 18:37:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050140, encodeId=3604205014067, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Dec 07 14:37:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652697, encodeId=152b165269ea1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 10 12:37:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524540, encodeId=cbb11524540e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594334, encodeId=2c0b1594334d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=)]
    2013-12-07 tastas

    #III期临床研究#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1649953, encodeId=ac9c16499533a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 26 09:37:00 CST 2013, time=2013-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915782, encodeId=ce391915e828d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu May 08 18:37:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050140, encodeId=3604205014067, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Dec 07 14:37:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652697, encodeId=152b165269ea1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 10 12:37:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524540, encodeId=cbb11524540e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594334, encodeId=2c0b1594334d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=)]
    2014-06-10 医生2402

    #I期临床#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1649953, encodeId=ac9c16499533a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 26 09:37:00 CST 2013, time=2013-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915782, encodeId=ce391915e828d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu May 08 18:37:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050140, encodeId=3604205014067, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Dec 07 14:37:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652697, encodeId=152b165269ea1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 10 12:37:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524540, encodeId=cbb11524540e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594334, encodeId=2c0b1594334d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=)]
    2013-08-15 guihongzh

    #II期临床#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1649953, encodeId=ac9c16499533a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Mon Aug 26 09:37:00 CST 2013, time=2013-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915782, encodeId=ce391915e828d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu May 08 18:37:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050140, encodeId=3604205014067, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Dec 07 14:37:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652697, encodeId=152b165269ea1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Jun 10 12:37:00 CST 2014, time=2014-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524540, encodeId=cbb11524540e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594334, encodeId=2c0b1594334d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 15 05:37:00 CST 2013, time=2013-08-15, status=1, ipAttribution=)]
    2013-08-15 智智灵药

    #III期#

    0

Baidu
map
Baidu
map
Baidu
map